Heron Therapeutics (NASDAQ:HRTX) Releases Earnings Results, Beats Expectations By $0.05 EPS

Heron Therapeutics (NASDAQ:HRTX) issued its earnings results on Thursday. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05, Zacks reports. The firm had revenue of $40.78 million for the quarter, compared to analysts’ expectations of $37.37 million. Heron Therapeutics updated its FY 2025 guidance to EPS.

Heron Therapeutics Stock Performance

Heron Therapeutics stock opened at $2.47 on Friday. The stock’s 50 day moving average price is $1.69 and its 200 day moving average price is $1.72. The firm has a market capitalization of $375.67 million, a PE ratio of -13.72 and a beta of 1.60. Heron Therapeutics has a one year low of $1.04 and a one year high of $3.93.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on HRTX. Needham & Company LLC reiterated a “buy” rating and set a $4.00 target price on shares of Heron Therapeutics in a report on Friday. StockNews.com raised Heron Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.